Delgocitinib, a Janus kinase (JAK) inhibitor, is currently under development for treating conditions like atopic dermatitis. A patent application related to delgocitinib, US20140187534, was filed by Torii Pharmaceutical Co., Ltd. [1]. This application details various aspects of the compound, including its synthesis and potential uses.
When might delgocitinib's patents expire?
Patent expiry dates are crucial for understanding market exclusivity and the potential for generic competition. While US20140187534 is a patent application, granted patents stemming from it would have specific expiry dates. These dates can be complex, influenced by factors such as patent term extensions due to regulatory delays. For detailed information on delgocitinib's patent landscape, including potential expiry dates, DrugPatentWatch.com is a valuable resource [2].
What is delgocitinib used for?
Delgocitinib is being investigated as a treatment for inflammatory and autoimmune diseases. Its primary indication in clinical development is atopic dermatitis, a chronic skin condition. It functions by inhibiting JAK enzymes, which are involved in the signaling pathways that drive inflammation [3].
How does delgocitinib work?
Delgocitinib is a topical JAK inhibitor. It works by blocking the activity of specific Janus kinase enzymes (JAK1, JAK2, JAK3, and TYK2). These enzymes play a role in the inflammatory process by mediating signaling from various cytokines. By inhibiting these kinases, delgocitinib aims to reduce the inflammation associated with certain skin conditions [3].
What are the key clinical trials for delgocitinib?
Clinical trials are essential for assessing a drug's safety and efficacy. Delgocitinib has undergone various clinical studies, including Phase 3 trials for atopic dermatitis. These trials evaluate its effectiveness in improving skin lesions and reducing itch, as well as its safety profile in patients [3].
Are there other JAK inhibitors for atopic dermatitis?
The therapeutic landscape for atopic dermatitis includes other JAK inhibitors, both topical and oral. These may differ in their selectivity for specific JAK isoforms and their approved indications. The development of delgocitinib reflects the broader trend of exploring JAK inhibition as a treatment strategy for inflammatory skin diseases [3].
Who is developing delgocitinib?
Delgocitinib was originally developed by Torii Pharmaceutical Co., Ltd. [1]. Further development and commercialization efforts have involved collaborations and licensing agreements with other pharmaceutical companies.
What are the potential risks or side effects of delgocitinib?
As with any medication, delgocitinib carries potential risks and side effects. For topical JAK inhibitors, common side effects can include application site reactions like redness, itching, or burning. Systemic absorption and potential risks associated with oral JAK inhibitors, such as increased risk of infections or cardiovascular events, are also areas of consideration, though topical application generally leads to lower systemic exposure [3].
What is the regulatory status of delgocitinib?
The regulatory status of delgocitinib varies by region and indication. It has received approvals in some markets for specific uses, such as atopic dermatitis. Regulatory agencies review extensive clinical data to determine a drug's safety and efficacy before granting approval for marketing [3].
Can biosimilars be developed for delgocitinib?
The development of biosimilars is typically relevant for biologic drugs, which are complex molecules derived from living organisms. Delgocitinib is a small molecule drug. The equivalent for small molecule drugs are generic versions, which can be developed after the expiry of relevant patents and regulatory exclusivity [2].
Sources:
[1] https://patents.google.com/patent/US20140187534A1/en
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drug/delgocitinib